BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. - Wikidata - awgldk - TriplyDB

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.

http://www.wikidata.org/entity/Q37235693

about

Harnessing the apoptotic programs in cancer stem-like cells Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.Targeting novel signaling pathways for resistant acute myeloid leukemia.Overview of the Use of Murine Models in Leukemia and Lymphoma Research.Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells.Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.Combined venetoclax and alvocidib in acute myeloid leukemia.Concise Review: Adaptation of the Bone Marrow Stroma in Hematopoietic Malignancies: Current Concepts and Models.

P2860

Q26801037-F2E6CC64-166D-4A00-8352-C4A0902C4813 Q28396457-FEA474DA-4EF8-4891-B67E-7ACC96138860 Q34232877-98892462-1E4A-43DE-ABA8-A00BDC40FFE8 Q35331086-7E1BB95B-1BF4-4DAC-9BFF-30C7096D4517 Q36413863-5353B0B9-921F-46AF-9D86-FBAC4AC7AF35 Q36507980-7A694EA3-FA2A-41D6-BD49-FEC9AF1ED8D0 Q36544893-9304E027-5B33-4DA3-A19C-60AC49D51761 Q37416797-010F96C1-C60B-4A70-8333-291CC995E102 Q38128358-2C63214F-581F-4798-B7F5-2440D6B1E6C5 Q38253011-56B9D37A-FA64-48FA-AEA9-D2A52B0D42FB Q38297507-E2732AFD-D633-4AC2-90BD-2E5BC227E4CC Q38749909-48E3A225-CF1A-448E-BB4C-C47DE44EABA1 Q38857427-BC2389AC-CBEF-42AF-BD83-6E5784AA2BF7 Q39929571-4D6947B7-D489-40B5-B3DE-AADCF848FA11 Q40759493-2952279D-11CF-4309-B8C8-13F56BF518E1 Q46370948-7F49AAC0-32DC-422E-8F3C-2DA0B7BC329F Q47105216-11EA0FB5-D6B3-48A0-83F3-937164D41411 Q48127861-DF474E28-1902-45EE-95A7-AFFF7582009B

P2860

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.

http://www.wikidata.org/entity/Q37235693

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

BCL-2 inhibition with ABT-737 ...... tive LSK and progenitor cells.

@en

BCL-2 inhibition with ABT-737 ...... tive LSK and progenitor cells.

@en-gb

BCL-2 inhibition with ABT-737 ...... tive LSK and progenitor cells.

@nl

type

label

BCL-2 inhibition with ABT-737 ...... tive LSK and progenitor cells.

@en

BCL-2 inhibition with ABT-737 ...... tive LSK and progenitor cells.

@en-gb

BCL-2 inhibition with ABT-737 ...... tive LSK and progenitor cells.

@nl

prefLabel

BCL-2 inhibition with ABT-737 ...... tive LSK and progenitor cells.

@en

BCL-2 inhibition with ABT-737 ...... tive LSK and progenitor cells.

@en-gb

BCL-2 inhibition with ABT-737 ...... tive LSK and progenitor cells.

@nl

P1433

Q37235693-D7F7D398-7D17-46C0-B0FC-9B3C67D20508

P1476

Q37235693-48346B3D-E822-4624-A585-46EC1C17C849

P2093

Q37235693-0772CEB7-03EE-4764-AA16-D580D2545353

Q37235693-0995C720-9C3C-499B-9FA8-33638E6EB28D

Q37235693-1491C9E2-C280-474F-9FD4-89B03C0FB36E

Q37235693-17C2D043-9778-4AC8-9437-A425C92E14F2

Q37235693-40B13610-24A3-4C0E-A48A-7CD3AAC9606A

Q37235693-63EDDCA2-E40B-4EAD-BF4D-8E66E4C969DB

Q37235693-6536588C-4F78-4A4B-96E5-28E67A52047F

Q37235693-66669A45-C718-4931-B390-66D985229777

Q37235693-696879FB-C0A6-4C6C-953C-2004818C4BD3

Q37235693-6EB1BA1C-315C-41EC-91E1-7C5F9B0F3F63

P2860

Q37235693-0087AE53-1502-443A-BBED-B95691FE2FBE

Q37235693-015B5A7A-5664-4ADA-8797-B2448AEAD1AB

Q37235693-03D9A9D4-7DC2-4795-A8B5-D1F58352549E

Q37235693-0AC286A6-4E84-4AB8-AA0E-294F6471B30B

Q37235693-0CEF297B-4EE8-402D-8A86-B38CB8E996A4

Q37235693-0EDF1381-F390-4F65-BEF4-C2986147E289

Q37235693-26A4E6CF-815E-462C-A192-82973A2C6C79

Q37235693-30B1B2F4-926B-40BC-A440-23E8246F8339

Q37235693-36D23761-2ABF-4643-B99A-D16F46EB6824

Q37235693-42D1FA16-B314-4269-BBEE-A7EEA1DF273E

P304

Q37235693-5B00D03C-1F52-478D-BD96-DEB2CAF6840A

P31

Q37235693-C49E6FD5-88A6-4ABB-8AC4-72ECF1EF11BB

P356

Q37235693-5327B463-579C-4157-B02B-1221C07F5C25

P407

Q37235693-8C7F7695-8131-48D8-89A4-2A93E0C0FF52

P433

Q37235693-1523216F-2FC5-44EF-9745-C1AE231F281C

P478

Q37235693-A7DC58B1-5A12-453C-A02C-BC4B7A5ABF8A

P50

Q37235693-04FAC22B-9F98-411E-92C0-EAAB014D8C40

Q37235693-0E03E104-4744-4EB7-A4A3-215DCEFBD9A4

Q37235693-2A33EC20-BBE8-49FC-BA38-28C02B97CB00

Q37235693-2BC13D1E-A45B-480B-AB84-7AD45D13A081

Q37235693-50245014-5D42-40A5-8EB8-C380070384DD

Q37235693-A2803791-3668-4711-B1AB-CFC0950E952A

Q37235693-B74DB215-ABB7-4305-8F07-FE51E29F1CC3

Q37235693-E4227B71-9C7E-48E2-9E9E-EDACE2EC45CA

P577

Q37235693-B764BABF-70E1-49AB-9E7D-17FEBA52B1EE

P5875

Q37235693-D1488EB9-CF94-4528-BC4F-B8BC0330B286

P698

Q37235693-EECC9841-ED8C-4D4B-A3FB-6EC5C3603773

P932

Q37235693-F2FE4ABF-004E-4C7B-B850-D9C86D59CC5B

P356

BLOOD-2012-07-445635

P1433

P1476

BCL-2 inhibition with ABT-737 ...... tive LSK and progenitor cells.

@en

P2093

Alice C Fan

http://www.w3.org/2001/XMLSchema#string

Andrea W Tu

http://www.w3.org/2001/XMLSchema#string

Anne Janin

http://www.w3.org/2001/XMLSchema#string

Anthony Whetton

http://www.w3.org/2001/XMLSchema#string

Carole Le Pogam

http://www.w3.org/2001/XMLSchema#string

Dean W Felsher

http://www.w3.org/2001/XMLSchema#string

Florence Hervatin

http://www.w3.org/2001/XMLSchema#string

Laure Sarda-Mantel

http://www.w3.org/2001/XMLSchema#string

Maria-Elena Noguera

http://www.w3.org/2001/XMLSchema#string

Marika Pla

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia

FAST DB: a website resource for the study of the expression regulation of human gene products.

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Splicing factor and exon profiling across human tissues.

P304

2864-2876

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-07-445635

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Christophe Leboeuf

Christine Chomienne

Marina Konopleva

Michael Andreeff

P577

2013-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255953165

http://www.w3.org/2001/XMLSchema#string

P698

23943652

http://www.w3.org/2001/XMLSchema#string

P932

3799000

http://www.w3.org/2001/XMLSchema#string